|
INBRX-106 Clinical Trials
2 actively recruiting trials across 2 locations
Also known as: Hexavalent OX40 agonist antibody
Duarte, California1 trial
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
City of Hope Medical Center
Phase 2/3
Los Angeles, California1 trial
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Ellison Institute of Technology (EITM)
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.